Literature DB >> 25107463

Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.

Tetsuo Hasegawa1, Yoshinobu Aisa, Kengo Shimazaki, Tomonori Nakazato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25107463     DOI： 10.1007/s00277-014-2182-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

Review 1.  Idelalisib in the management of lymphoma.

Authors:  Chan Yoon Cheah; Nathan H Fowler
Journal:  Blood       Date:  2016-06-01       Impact factor: 22.113

2.  Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.

Authors:  Yosuke Matsumoto; Tsutomu Kobayashi; Yuji Shimura; Eri Kawata; Hisao Nagoshi; Muneo Ohshiro; Mio Sugitani; Kazuho Shimura; Toshiki Iwai; Shin-Ichi Fuchida; Mihoko Yoshida; Miki Kiyota; Shinsuke Mizutani; Yoshiaki Chinen; Tomoko Takimoto-Shimomura; Mitsushige Nakao; Hiroto Kaneko; Hitoji Uchiyama; Nobuhiko Uoshima; Hikari Nishigaki; Yutaka Kobayashi; Shigeo Horiike; Chihiro Shimazaki; Masafumi Taniwaki; Junya Kuroda
Journal:  Int J Hematol       Date:  2019-05-24       Impact factor: 2.319

3.  Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets.

Authors:  Andrea Cona; Daniele Tesoro; Margherita Chiamenti; Esther Merlini; Daris Ferrari; Antonio Marti; Carla Codecà; Giuseppe Ancona; Camilla Tincati; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  BMC Infect Dis       Date:  2019-10-22       Impact factor: 3.090

4.  Herpetic esophagitis following bendamustine-containing regimen.

Authors:  Hiromichi Yamane; Yasumasa Monobe; Tomohiro Tanikawa; Nobuaki Ochi; Yoshihiro Honda; Hirofumi Kawamoto; Nagio Takigawa
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

5.  Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.

Authors:  H Saito; D Maruyama; A M Maeshima; S Makita; H Kitahara; K Miyamoto; S Fukuhara; W Munakata; T Suzuki; Y Kobayashi; H Taniguchi; K Tobinai
Journal:  Blood Cancer J       Date:  2015-10-23       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.